The only trial where a large number of elderly patients (about 40%) were enrolled is the “Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48” (ENGAGE-AF TIMI 48). The gene discussed is F10; the disease is atrial fibrillation.